Free tool
FAERS Monitor: Remeron Soltab
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021208 or its brand name (Remeron Soltab, Mirtazapine). Reports on generic versions are filed under their own applications.
Reports
76,416
Serious
66,432
87% of reports
Hospitalization
31,878
Death reported
12,226
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue4,001
- nausea3,967
- drug ineffective3,857
- toxicity to various agents3,802
- fall3,461
- off label use3,442
- diarrhoea3,394
- drug interaction3,117
- dizziness2,985
- death2,898
- dyspnoea2,852
- anxiety2,759
- vomiting2,709
- somnolence2,600
- confusional state2,590
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 547 |
| 2005 | 730 |
| 2006 | 808 |
| 2007 | 882 |
| 2008 | 957 |
| 2009 | 1,143 |
| 2010 | 1,379 |
| 2011 | 1,836 |
| 2012 | 1,913 |
| 2013 | 1,817 |
| 2014 | 2,304 |
| 2015 | 2,879 |
| 2016 | 3,351 |
| 2017 | 3,947 |
| 2018 | 5,569 |
| 2019 | 6,224 |
| 2020 | 6,278 |
| 2021 | 5,491 |
| 2022 | 5,684 |
| 2023 | 5,871 |
| 2024 | 5,817 |
| 2025 | 6,213 |
| 2026 | 4,774 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,977,743 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| toxicity to various agentsSignal | 3,802 | 6.3 | 6.1 | 16,792 |
| drug interactionSignal | 3,117 | 5.5 | 5.3 | 11,321 |
| confusional stateSignal | 2,590 | 4.5 | 4.3 | 6,908 |
| somnolenceSignal | 2,600 | 3.6 | 3.5 | 4,833 |
| fallSignal | 3,461 | 2.9 | 2.8 | 4,274 |
| anxietySignal | 2,759 | 2.7 | 2.6 | 2,926 |
| dizziness | 2,985 | 1.7 | 1.6 | 780 |
| vomiting | 2,709 | 1.6 | 1.5 | 601 |
| diarrhoea | 3,394 | 1.4 | 1.4 | 485 |
| fatigue | 4,001 | 1.4 | 1.4 | 506 |
| dyspnoea | 2,852 | 1.4 | 1.3 | 317 |
| nausea | 3,967 | 1.4 | 1.3 | 432 |
| off label use | 3,442 | 1.1 | 1.0 | 22 |
| death | 2,898 | 0.9 | 0.9 | 18 |
| drug ineffective | 3,857 | 0.8 | 0.8 | 194 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.